148 related articles for article (PubMed ID: 20207871)
1. Risk factors for acute kidney injury in visceral leishmaniasis (Kala-Azar).
Oliveira MJ; Silva Júnior GB; Abreu KL; Rocha NA; Garcia AV; Franco LF; Mota RM; Libório AB; Daher EF
Am J Trop Med Hyg; 2010 Mar; 82(3):449-53. PubMed ID: 20207871
[TBL] [Abstract][Full Text] [Related]
2. Historical series of patients with visceral leishmaniasis treated with meglumine antimoniate in a hospital for tropical diseases, Maceió-AL, Brazil.
Silveira LJ; Rocha TJ; Ribeiro SA; Pedrosa CM
Rev Inst Med Trop Sao Paulo; 2015; 57(1):33-8. PubMed ID: 25651324
[TBL] [Abstract][Full Text] [Related]
3. Treatment of kala-azar in India.
Thakur CP
Natl Med J India; 1992; 5(5):203-5. PubMed ID: 1338871
[No Abstract] [Full Text] [Related]
4. Pediatric visceral leishmaniasis in Western Sicily, Italy: a retrospective analysis of 111 cases.
Cascio A; Colomba C; Antinori S; Orobello M; Paterson D; Titone L
Eur J Clin Microbiol Infect Dis; 2002 Apr; 21(4):277-82. PubMed ID: 12072938
[TBL] [Abstract][Full Text] [Related]
5. Amphotericin B lipid complex versus meglumine antimoniate in the treatment of visceral leishmaniasis in patients infected with HIV: a randomized pilot study.
Laguna F; Videla S; Jiménez-Mejías ME; Sirera G; Torre-Cisneros J; Ribera E; Prados D; Clotet B; Sust M; López-Vélez R; Alvar J;
J Antimicrob Chemother; 2003 Sep; 52(3):464-8. PubMed ID: 12888588
[TBL] [Abstract][Full Text] [Related]
6. Post-kala-azar dermal leishmaniasis (PKDL) developing after treatment of visceral leishmaniasis with amphotericin B and miltefosine.
Kumar D; Ramesh V; Verma S; Ramam M; Salotra P
Ann Trop Med Parasitol; 2009 Dec; 103(8):727-30. PubMed ID: 20030997
[No Abstract] [Full Text] [Related]
7. [Treatment of visceral leishmaniasis or kala-azar (author's transl)].
Laroche R; Sirol J; Poli L
Med Trop (Mars); 1978; 38(4):401-4. PubMed ID: 215868
[No Abstract] [Full Text] [Related]
8. Efficacy and safety of amphotericin B deoxycholate versus N-methylglucamine antimoniate in pediatric visceral leishmaniasis: an open-label, randomized, and controlled pilot trial in Brazil.
Borges MM; Pranchevicius MC; Noronha EF; Romero GA; Carranza-Tamayo CO
Rev Soc Bras Med Trop; 2017; 50(1):67-74. PubMed ID: 28327804
[TBL] [Abstract][Full Text] [Related]
9. Recent advances in the treatment of visceral leishmaniasis.
Davidson RN; Croft SL
Trans R Soc Trop Med Hyg; 1993; 87(2):130-1, 141. PubMed ID: 8393221
[No Abstract] [Full Text] [Related]
10. Sodium antimony gluconate, amphotericin, and myocardial damage.
Thakur CP
Lancet; 1998 Jun; 351(9120):1928-9. PubMed ID: 9654264
[No Abstract] [Full Text] [Related]
11. Efficacy and safety of available treatments for visceral leishmaniasis in Brazil: A multicenter, randomized, open label trial.
Romero GAS; Costa DL; Costa CHN; de Almeida RP; de Melo EV; de Carvalho SFG; Rabello A; de Carvalho AL; Sousa AQ; Leite RD; Lima SS; Amaral TA; Alves FP; Rode J;
PLoS Negl Trop Dis; 2017 Jun; 11(6):e0005706. PubMed ID: 28662034
[TBL] [Abstract][Full Text] [Related]
12. Chemotherapy of leishmaniasis in India.
Thakur CP
Indian J Pediatr; 1987; 54(1):7-10. PubMed ID: 3030933
[No Abstract] [Full Text] [Related]
13. Cumulative cardiac toxicity of sodium stibogluconate and amphotericin B in treatment of kala-azar.
Maheshwari A; Seth A; Kaur S; Aneja S; Rath B; Basu S; Patel R; Dutta AK
Pediatr Infect Dis J; 2011 Feb; 30(2):180-1. PubMed ID: 20823781
[TBL] [Abstract][Full Text] [Related]
14. [Treatment of infantile visceral leishmaniasis].
Minodier P; Faraut-Gambarelli F; Piarroux R; Gire C; Garnier JM; Dumon H
Arch Pediatr; 1999 Jan; 6(1):59-66. PubMed ID: 9974099
[TBL] [Abstract][Full Text] [Related]
15. Leishmaniasis: an update of current pharmacotherapy.
Sundar S; Chakravarty J
Expert Opin Pharmacother; 2013 Jan; 14(1):53-63. PubMed ID: 23256501
[TBL] [Abstract][Full Text] [Related]
16. Pediatric visceral leishmaniasis in southern France.
Minodier P; Piarroux R; Garnier JM; Unal D; Perrimond H; Dumon H
Pediatr Infect Dis J; 1998 Aug; 17(8):701-4. PubMed ID: 9726344
[TBL] [Abstract][Full Text] [Related]
17. [Clinico-epidemiological study of kala-azar in the south of Madrid].
de la Serna FJ; Salto E; Valdés D; Vos Saus R
Rev Sanid Hig Publica (Madr); 1987; 61(7-8):783-98. PubMed ID: 3438697
[No Abstract] [Full Text] [Related]
18. A male preponderance in patients with Indian post kala-azar dermal leishmaniasis is associated with increased circulating levels of testosterone.
Mukhopadhyay D; Mukherjee S; Ghosh S; Roy S; Saha B; Das NK; Chatterjee M
Int J Dermatol; 2016 May; 55(5):e250-5. PubMed ID: 26536363
[TBL] [Abstract][Full Text] [Related]
19. [Nephrotic syndrome and acute pancreatitis related to glucantime administration].
Valencia ME; Laguna F; González Lahoz J
An Med Interna; 2000 Jan; 17(1):54. PubMed ID: 10730416
[No Abstract] [Full Text] [Related]
20. Treatment of paediatric visceral leishmaniasis: amphotericin B or pentavalent antimony compounds?
Kafetzis DA; Velissariou IM; Stabouli S; Mavrikou M; Delis D; Liapi G
Int J Antimicrob Agents; 2005 Jan; 25(1):26-30. PubMed ID: 15620822
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
